MTOR and neoplasm: Although MTOR inhibitors have been identified as potential targets for treating tRCC36,37, this signal appeared only when we compared matched tumor and normal samples (BP:0002224, Padj = 1.5 × 10−5), suggesting that the MTOR signaling pathway is less prominent than the metabolic pathway that we investigated (Supplementary Figs. 4 and 5).